George L Bakris

Summary

Affiliation: Rush University Medical Center
Country: USA

Publications

  1. doi request reprint Renal outcomes with different fixed-dose combination therapies in patients with hypertension at high risk for cardiovascular events (ACCOMPLISH): a prespecified secondary analysis of a randomised controlled trial
    George L Bakris
    Hypertensive Diseases Unit, Department of Medicine, University of Chicago Pritzker School of Medicine, Chicago, IL 60637, USA
    Lancet 375:1173-81. 2010
  2. ncbi request reprint Efficacy of a once-daily formulation of carvedilol for the treatment of hypertension
    Michael A Weber
    State University of New York Downstate College of Medicine, Brooklyn, NY, USA
    J Clin Hypertens (Greenwich) 8:840-9. 2006
  3. ncbi request reprint Appropriate dose transition to a controlled-release formulation of carvedilol in patients with hypertension
    George L Bakris
    Hypertensive Diseases Unit, Section of Endocrinology, Diabetes, and Metabolism, University of Chicago Pritzker School of Medicine, Chicago, Illinois, USA
    Rev Cardiovasc Med 9:96-105. 2008
  4. ncbi request reprint Clinical outcomes in the diabetes cohort of the INternational VErapamil SR-Trandolapril study
    George L Bakris
    Rush Medical University, 1700 W Van Buren St, Suite 470, Chicago, IL
    Hypertension 44:637-42. 2004
  5. ncbi request reprint Protecting renal function in the hypertensive patient: clinical guidelines
    George L Bakris
    Department of Preventive Medicine, Rush University Medical Center, Chicago, Illinois 60612, USA
    Am J Hypertens 18:112S-119S. 2005
  6. ncbi request reprint Preventing hypertensive kidney disease: the critical role of combination therapy
    George L Bakris
    Department of Preventive Medicine, Rush University Medical Center, Chicago, Illinois 60612, USA
    Am J Hypertens 18:93S-94S. 2005
  7. ncbi request reprint Advanced glycation end-product cross-link breakers. A novel approach to cardiovascular pathologies related to the aging process
    George L Bakris
    Department of Preventive Medicine, Rush University Medical Center, Chicago, Illinois 60612, USA
    Am J Hypertens 17:23S-30S. 2004
  8. ncbi request reprint Implications of albuminuria on kidney disease progression
    George L Bakris
    Rush University Hypertension Center, Rush University Medical Center, 1700 West Van Buren Street, Suite 470, Chicago, IL 60612, USA
    J Clin Hypertens (Greenwich) 6:18-22. 2004
  9. ncbi request reprint Clinical importance of microalbuminuria in diabetes and hypertension
    George L Bakris
    Rush University Hypertension Center, Rush University Medical Center, 1700 W Van Buren Street, Suite 470, Chicago, IL 60612, USA
    Curr Hypertens Rep 6:352-6. 2004
  10. ncbi request reprint Differential effects of beta-blockers on albuminuria in patients with type 2 diabetes
    George L Bakris
    Rush University Medical Center, Chicago, IL 60612, USA
    Hypertension 46:1309-15. 2005

Collaborators

Detail Information

Publications116 found, 100 shown here

  1. doi request reprint Renal outcomes with different fixed-dose combination therapies in patients with hypertension at high risk for cardiovascular events (ACCOMPLISH): a prespecified secondary analysis of a randomised controlled trial
    George L Bakris
    Hypertensive Diseases Unit, Department of Medicine, University of Chicago Pritzker School of Medicine, Chicago, IL 60637, USA
    Lancet 375:1173-81. 2010
    ..We assessed the effects of these drug combinations on progression of chronic kidney disease...
  2. ncbi request reprint Efficacy of a once-daily formulation of carvedilol for the treatment of hypertension
    Michael A Weber
    State University of New York Downstate College of Medicine, Brooklyn, NY, USA
    J Clin Hypertens (Greenwich) 8:840-9. 2006
    ..Adverse events, including clinical chemistry values, were similar in the drug-treated and placebo groups. Carvedilol CR has a clinically meaningful defined dose-dependent antihypertensive effect that persists throughout a 24-hour period...
  3. ncbi request reprint Appropriate dose transition to a controlled-release formulation of carvedilol in patients with hypertension
    George L Bakris
    Hypertensive Diseases Unit, Section of Endocrinology, Diabetes, and Metabolism, University of Chicago Pritzker School of Medicine, Chicago, Illinois, USA
    Rev Cardiovasc Med 9:96-105. 2008
    ..The use of carvedilol CR (once daily) may be preferable to a twice-daily regimen...
  4. ncbi request reprint Clinical outcomes in the diabetes cohort of the INternational VErapamil SR-Trandolapril study
    George L Bakris
    Rush Medical University, 1700 W Van Buren St, Suite 470, Chicago, IL
    Hypertension 44:637-42. 2004
    ..Thus, a verapamil SR-based antihypertensive treatment strategy is an alternative to a beta-blocker-based strategy in adults with CAD and diabetes...
  5. ncbi request reprint Protecting renal function in the hypertensive patient: clinical guidelines
    George L Bakris
    Department of Preventive Medicine, Rush University Medical Center, Chicago, Illinois 60612, USA
    Am J Hypertens 18:112S-119S. 2005
    ..This is achieved optimally by using agents that block the renin-angiotensin system in concert with other agents that reduce proteinuria and BP...
  6. ncbi request reprint Preventing hypertensive kidney disease: the critical role of combination therapy
    George L Bakris
    Department of Preventive Medicine, Rush University Medical Center, Chicago, Illinois 60612, USA
    Am J Hypertens 18:93S-94S. 2005
  7. ncbi request reprint Advanced glycation end-product cross-link breakers. A novel approach to cardiovascular pathologies related to the aging process
    George L Bakris
    Department of Preventive Medicine, Rush University Medical Center, Chicago, Illinois 60612, USA
    Am J Hypertens 17:23S-30S. 2004
    ..Additional clinical studies to determine the utility of alagebrium in treating cardiovascular disorders associated with aging are in progress...
  8. ncbi request reprint Implications of albuminuria on kidney disease progression
    George L Bakris
    Rush University Hypertension Center, Rush University Medical Center, 1700 West Van Buren Street, Suite 470, Chicago, IL 60612, USA
    J Clin Hypertens (Greenwich) 6:18-22. 2004
    ..Use of an angiotensin receptor blocker added to an angiotensin-converting enzyme inhibitor or vice versa can further lower albuminuria by an additional 30%-40%, which is not true of the additional lowering of BP...
  9. ncbi request reprint Clinical importance of microalbuminuria in diabetes and hypertension
    George L Bakris
    Rush University Hypertension Center, Rush University Medical Center, 1700 W Van Buren Street, Suite 470, Chicago, IL 60612, USA
    Curr Hypertens Rep 6:352-6. 2004
    ..Further lowering of albuminuria may be achieved by adding verapamil, diltiazem, or an ARB to an ACE inhibitor...
  10. ncbi request reprint Differential effects of beta-blockers on albuminuria in patients with type 2 diabetes
    George L Bakris
    Rush University Medical Center, Chicago, IL 60612, USA
    Hypertension 46:1309-15. 2005
    ..These differences cannot be explained by effects on blood pressure or alpha1-antagonism but may relate to antioxidant properties of carvedilol...
  11. doi request reprint The message for World Kidney Day 2009: hypertension and kidney disease: a marriage that should be prevented
    George L Bakris
    Hypertensive Diseases Unit, Department of Medicine, Pritzker School of Medicine, University of Chicago, Chicago, IL, USA
    J Clin Hypertens (Greenwich) 11:144-7. 2009
    ..Therefore, treatment of hypertension has become the most important intervention in the management of all forms of CKD. For this reason, World Kidney Day on March 12, 2009 will emphasize the role of hypertension...
  12. ncbi request reprint Dual therapy in hypertensive patients with coronary artery disease: the role of calcium channel blockers and beta-blockers
    George L Bakris
    University of Chicago School of Medicine, Department of Medicine, Hypertensive Diseases Unit, Chicago, Illinois 60637, USA
    Am J Cardiovasc Drugs 7:25-9. 2007
    ....
  13. doi request reprint Hypertension in early-stage kidney disease: an update from the Kidney Early Evaluation Program (KEEP)
    Rigas Kalaitzidis
    Department of Medicine, Hypertensive Diseases Unit, Section of Endocrinology, Diabetes and Metabolism, University of Chicago, Pritzker School of Medicine, Chicago, IL 60637, USA
    Am J Kidney Dis 53:S22-31. 2009
    ..Chronic kidney disease (CKD) is a worldwide public health problem. Systolic blood pressure as an associated feature of CKD has not been fully explored in community volunteer and nationally representative samples of the US population...
  14. doi request reprint Antihypertensive efficacy of hydrochlorothiazide vs chlorthalidone combined with azilsartan medoxomil
    George L Bakris
    The University of Chicago Medicine, Chicago, IL 60637, USA
    Am J Med 125:1229.e1-1229.e10. 2012
    ..This study provides a direct comparison of chlorthalidone with hydrochlorothiazide, each combined with the angiotensin receptor blocker azilsartan medoxomil, on blood pressure reduction and control rates...
  15. doi request reprint Telmisartan is more effective than losartan in reducing proteinuria in patients with diabetic nephropathy
    George Bakris
    Department of Medicine, Pritzker School of Medicine, University of Chicago, Chicago, Illinois, USA
    Kidney Int 74:364-9. 2008
    ..We conclude that telmisartan is superior to losartan in reducing proteinuria in hypertensive patients with diabetic nephropathy, despite a similar reduction in blood pressure...
  16. ncbi request reprint The rationale and design of the Glycemic Effects in Diabetes Mellitus Carvedilol-Metoprolol Comparison in Hypertensives (GEMINI) trial
    George L Bakris
    Rush Hypertension Center, Rush Medical Center, Suite 470, 1700 W Van Buren, Chicago, IL 60612, USA
    J Diabetes Complications 19:74-9. 2005
    ..The GEMINI trial, therefore, is the first large randomized trial to assess whether utilizing a third-generation beta-blocker yields a favorable metabolic profile in the patient with Type 2 diabetes and hypertension...
  17. doi request reprint Randomized study of antihypertensive efficacy and safety of combination aliskiren/valsartan vs valsartan monotherapy in hypertensive participants with type 2 diabetes mellitus
    George L Bakris
    Department of Medicine, Comprehensive Hypertension Center, The University of Chicago Medicine, Chicago, IL 60637, USA
    J Clin Hypertens (Greenwich) 15:92-100. 2013
    ..0 mEq/L. Combination aliskiren/valsartan has additive effects on blood pressure reduction and tolerability similar to valsartan in hypertensive/diabetic participants with early-stage (stages 1 and 2) CKD...
  18. doi request reprint Plasma parathyroid hormone level and prevalent cardiovascular disease in CKD stages 3 and 4: an analysis from the Kidney Early Evaluation Program (KEEP)
    Rohit Bhuriya
    Department of Medicine, Chicago Medical School, North Chicago, IL, USA
    Am J Kidney Dis 53:S3-10. 2009
    ..This analysis aims to assess whether serum intact parathyroid hormone (PTH) level is an independent risk factor for CVD in patients with CKD stages 3 and 4...
  19. ncbi request reprint The current state of RAAS blockade in the treatment of hypertension and proteinuria
    Rigas G Kalaitzidis
    Hypertension Diseases Unit, University of Chicago Pritzker School of Medicine, MC1027, Room P 328A, 5841 South Maryland Avenue, Chicago, IL 60637, USA
    Curr Cardiol Rep 11:436-42. 2009
    ..Increases in proteinuria, in spite of blood pressure reduction, are associated with faster declines in kidney function regardless of whether RAAS blockers are used...
  20. doi request reprint Hypertension awareness, treatment, and control in chronic kidney disease
    Pantelis A Sarafidis
    Hypertensive Diseases Unit, Section of Endocrinology, Diabetes, and Metabolism, University of Chicago Pritzker School of Medicine, Chicago, IL 60637, USA
    Am J Med 121:332-40. 2008
    ..The objective of this study was to determine the state of blood pressure control in patients with chronic kidney disease...
  21. ncbi request reprint Antihypertensive therapy in the presence of proteinuria
    Pantelis A Sarafidis
    Hypertension Clinical Research Center, Department of Preventive Medicine, Rush University Medical Center, Chicago, IL, USA
    Am J Kidney Dis 49:12-26. 2007
    ....
  22. ncbi request reprint Evaluation and treatment of patients with systemic hypertension
    Jay Garg
    Rush University Hypertension Center, Department of Preventive Medicine, Rush Presbyterian St Luke s Medical Center, Chicago, IL 60612, USA
    Circulation 105:2458-61. 2002
  23. ncbi request reprint Metabolic effects of carvedilol vs metoprolol in patients with type 2 diabetes mellitus and hypertension: a randomized controlled trial
    George L Bakris
    Department of Preventive Medicine, Rush University Medical Center, Chicago, Ill, USA
    JAMA 292:2227-36. 2004
    ..Beta-blockers have been shown to decrease cardiovascular risk in patients with hypertension and type 2 diabetes mellitus (DM); however, some components of the metabolic syndrome are worsened by some beta-blockers...
  24. doi request reprint ASH position paper: treatment of hypertension in patients with diabetes-an update
    George L Bakris
    Hypertensive Diseases and Diabetes Center, Department of Medicine, University of Chicago Pritzker School of Medicine, Chicago, IL 60637, USA
    J Clin Hypertens (Greenwich) 10:707-13; discussion 714-5. 2008
    ..Last, an updated algorithm is provided that incorporates many of the new findings and is suggested as a starting point to achieve blood pressure goals...
  25. ncbi request reprint Serum creatinine vs. albuminuria as biomarkers for the estimation of cardiovascular risk
    Rigas G Kalaitzidis
    Department of Medicine, Hypertensive Diseases Unit, University of Chicago, Pritzker School of Medicine, Chicago, IL 60637, USA
    Curr Vasc Pharmacol 8:604-11. 2010
    ..Thus, concomitant evaluation of both biomarkers eGFR and albuminuria is recommended to assess kidney function and CV risk thoroughly...
  26. ncbi request reprint Optimal treatment of hypertension in African Americans. Reaching and maintaining target blood pressure goals
    George L Bakris
    Departments of Preventive Medicine and Internal Medicine, Rush Hypertension Clinical Research Center, Rush Presbyterian St Luke s Medical Center, 1700 W Van Buren St, Suite 470, Chicago, IL 60612, USA
    Postgrad Med 112:73-4, 77-80, 83-4. 2002
    ..This article describes current "best practice" guidance on appropriate treatment of high blood pressure in African Americans. Two patient scenarios offer insight into clinical strategies...
  27. doi request reprint Effect of combining extended-release carvedilol and lisinopril in hypertension: results of the COSMOS study
    George L Bakris
    University of Chicago School of Medicine, Chicago, IL 60637, USA
    J Clin Hypertens (Greenwich) 12:678-86. 2010
    ..The tolerability profile of initiating combination therapy was generally comparable to the initiation of treatment with monotherapy...
  28. pmc Recognition, pathogenesis, and treatment of different stages of nephropathy in patients with type 2 diabetes mellitus
    George L Bakris
    University of Chicago Pritzker School of Medicine, 5841 S Maryland Ave, Chicago, IL 60637, USA
    Mayo Clin Proc 86:444-56. 2011
    ..Regular and comprehensive follow-up assessments with appropriate adjustment of the therapeutic regimen to maintain risk factor control is a vital component of care, including referral to specialists, when required...
  29. ncbi request reprint Newer renin-angiotensin-aldosterone system blocker combinations: is there an advantage?
    Ivana Lazich
    Hypertensive Diseases Unit, University of Chicago, Pritzker School of Medicine, Chicago, Illinois 60637, USA
    Curr Opin Nephrol Hypertens 20:471-5. 2011
    ....
  30. ncbi request reprint Effects of blood pressure level on progression of diabetic nephropathy: results from the RENAAL study
    George L Bakris
    Department of Preventive Medicine, Rush Presbyterian St Luke s Medical Center, Rush Medical College, Chicago, IL 60612, USA
    Arch Intern Med 163:1555-65. 2003
    ..Clinical trials of nephropathy in people with type 2 diabetes mellitus have not examined the effects of systolic blood pressure (SBP) or pulse pressure (PP) on the time to end-stage renal disease (ESRD) or death...
  31. ncbi request reprint Combined therapy with a calcium channel blocker and an angiotensin II type 1 receptor blocker
    George L Bakris
    University of Chicago, Pritzker School of Medicine, Chicago, IL 60637, USA
    J Clin Hypertens (Greenwich) 10:27-32. 2008
    ..The combination of amlodipine and an angiotensin II receptor blocker is well tolerated, including in patients with stage 2 hypertension and the elderly...
  32. ncbi request reprint The evolution of treatment guidelines for diabetic nephropathy. Strategies integrate JNC VI, more recent protocols
    George L Bakris
    Deparments of Preventive Medicine and Internal Medicine, Rush Hypertension Clinical Research Center, Rush Presbyterian St Luke s Medical Center, 1700 W Van Buren St, Suite 470, Chicago, IL 60612, USA
    Postgrad Med 113:35-40, 43-4, 50. 2003
    ..He describes their backing in research findings and outlines practical antihypertensive and renoprotective therapies to curtail risks of nephropathy and cardiovascular disease in patients with diabetes...
  33. ncbi request reprint Diabetes and chronic kidney disease: tragedy and challenge
    Dave Y Chua
    Department of Preventive Medicine, Rush University Hypertension Clinical Research Center, Rush Presbyterian St Luke s Medical Center, Chicago, IL 60612, USA
    Blood Purif 22:130-5. 2004
    ....
  34. ncbi request reprint Comparative efficacy of two different beta-blockers on 24-hour blood pressure control
    Pantelis Sarafidis
    Rush University Hypertension Clinical Research Center, Department of Preventive Medicine, Chicago, IL, USA
    J Clin Hypertens (Greenwich) 10:112-8. 2008
    ..It is possible that differences in outcome between atenolol-based and other therapies may be the result of inadequate dosing of atenolol, a medication that may not be effective for the entire 24-hour period...
  35. doi request reprint Blood pressure targets for patients with diabetes or kidney disease
    Colleen Flynn
    Hypertensive Diseases Unit, Section of Endocrinology, Diabetes and Metabolism, University of Chicago Pritzker School of Medicine, Chicago, IL 60637, USA
    Curr Hypertens Rep 13:452-5. 2011
    ..e., history of prior stroke or several risk factors for stroke, including hypertension, smoking, diabetes mellitus, dyslipidemia)...
  36. pmc Slowing nephropathy progression: focus on proteinuria reduction
    George L Bakris
    Hypertensive Diseases Unit, Section of Endocrinology, Diabetes and Metabolism, Pritzker School of Medicine, University of Chicago, Chicago, Illinois 60637, USA
    Clin J Am Soc Nephrol 3:S3-10. 2008
    ..These agents also reduce proteinuria, a risk marker for renal disease progression. Accumulating evidence indicates that their antiproteinuric effect correlates with their additional renal benefits...
  37. ncbi request reprint Blood pressure control in the patient with difficult-to-control hypertension: which agent for which patient?
    George L Bakris
    University of Chicago, IL, USA
    Prev Cardiol 11:42-9. 2008
    ..The authors maintained full control of the discussion and the resulting content of this article...
  38. doi request reprint Hypertension goals in advanced-stage kidney disease
    Keith Hopkins
    Department of Medicine, Section of Endocrinology, Diabetes and Metabolism, Hypertensive Diseases Unit, University of Chicago Pritzker School of Medicine, Chicago, Illinois, USA
    Clin J Am Soc Nephrol 4:S92-4. 2009
    ..Aggressive volume control seems key to maintaining good BP control. Once a valid time and measure for BP is agreed on, a clinical outcome trial is needed to test its utility...
  39. ncbi request reprint Cardiovascular risk factors in hypertension: rationale and design of studies to investigate the effects of controlled-release carvedilol on regression of left ventricular hypertrophy and lipid profile
    George L Bakris
    Hypertension Unit, Section of Endocrinology, Diabetes, and Metabolism, University of Chicago Pritzker School of Medicine, Chicago, Illinois 60637, USA
    Am J Cardiol 98:46L-52L. 2006
    ..These will be the first head-to-head trials using carvedilol CR to determine whether the differing pharmacologic actions among beta-blockers result in varying effects on cardiovascular risk factors...
  40. doi request reprint Should proteinuria reduction be the criterion for antihypertensive drug selection for patients with kidney disease?
    Rigas G Kalaitzidis
    Department of Medicine, Hypertensive Diseases Unit, University of Chicago Pritzker School of Medicine, Chicago, Illinois 60637, USA
    Curr Opin Nephrol Hypertens 18:386-91. 2009
    ....
  41. ncbi request reprint The message for World Kidney Day 2009: hypertension and kidney disease--a marriage that should be prevented
    George L Bakris
    Department of Medicine, Hypertensive Diseases Unit, University of Chicago, Pritzker School of Medicine, Chicago, Illinois, USA
    J Hypertens 27:666-9. 2009
    ..Therefore, treatment of hypertension has become the most important intervention in the management of all forms of CKD. For this reason, the forthcoming World Kidney Day on 12 March 2009 will emphasize the role of hypertension...
  42. ncbi request reprint The role of calcium antagonists in chronic kidney disease
    Casey N Gashti
    Rush University Hypertension Clinical Research Centre, Department of Preventive Medicine, Rush Presbyterian St Luke s Medical Centre, Chicago, Illinois 60612, USA
    Curr Opin Nephrol Hypertens 13:155-61. 2004
    ..To review goals of antihypertensive treatment in chronic kidney disease in the context of what role calcium antagonists play toward reducing progression of kidney disease...
  43. doi request reprint Fixed-dose combination and chronic kidney disease progression: which is the best?
    Keith A Hopkins
    Hypertensive Diseases Unit, Department of Medicine, The University of Chicago Pritzker School of Medicine, Chicago, Illinois, USA
    Curr Opin Nephrol Hypertens 19:450-5. 2010
    ..Use of combination therapy whether fixed dose or separate pill combinations is becoming more prevalent. Physicians are not routinely trained in using combinations of different antihypertensive medicines...
  44. ncbi request reprint Noninsulin glucose-lowering agents for the treatment of patients on dialysis
    Colleen Flynn
    American Society of Hypertension Comprehensive Hypertension Center, Section of Endocrinology, Diabetes and Metabolism, The University of Chicago Medicine, Chicago, IL 60637, USA
    Nat Rev Nephrol 9:147-53. 2013
    ..In this Review, we provide an overview of the use of noninsulin glucose-lowering agents in the dialysis population...
  45. ncbi request reprint Pros and cons of aggressive blood pressure lowering in patients with type 2 diabetes
    Rigas G Kalaitzidis
    Hypertensive Diseases Unit, University of Chicago Pritzker School of Medicine, Chicago, IL 60637, USA
    Curr Vasc Pharmacol 10:156-61. 2012
    ..This review examines the data for and against aggressive BP lowering in patients with diabetes...
  46. doi request reprint Hypertensive nephropathy: prevention and treatment recommendations
    Peter D Hart
    Cook County Stroger Hospital, Division of Nephrology, Department of Medicine, Chicago, IL 60612, USA
    Expert Opin Pharmacother 11:2675-86. 2010
    ..In particular, rational use of renin-angiotensin-aldosterone (RAAS) blockers and achieving blood pressure targets are crucial to reduce cardiovascular and renal outcomes...
  47. ncbi request reprint Management of hypertension in the cardiometabolic syndrome and diabetes
    Nitin Khosla
    Rush University Hypertension Center, Rush University Medical Center, 1700 W Van Buren Street, Suite 470, Chicago, IL 60612, USA
    Curr Diab Rep 4:199-205. 2004
    ..Thus, treating the cardiometabolic syndrome requires an aggressive approach with a focus on both lifestyle modification and pharmacologic intervention...
  48. ncbi request reprint Microalbuminuria in diabetes: focus on cardiovascular and renal risk reduction
    George L Bakris
    Rush University Hypertension Center, Department of Preventive Medicine, Rush Presbyterian St Luke s Medical Center, 1700 W Van Buren Street, Suite 470, Chicago, IL 60612, USA
    Curr Diab Rep 2:258-62. 2002
    ..In this article we explore evidence for albuminuria being an integral component of the cardiometabolic syndrome and a risk factor for cardiovascular disease and stroke...
  49. ncbi request reprint Comparative antihypertensive efficacy of angiotensin receptor blocker-based treatment in African-American and white patients
    George L Bakris
    Department of Preventive Medicine, Rush University Medical Center, Chicago, IL 60612, USA
    J Clin Hypertens (Greenwich) 7:587-95; quiz 596-7. 2005
    ..We conclude that an angiotensin receptor blocker as part of a BP-lowering strategy is effective in previously untreated African-American patients, although a higher proportion will require the use of a diuretic compared with Caucasians...
  50. ncbi request reprint Monitoring and managing urinary albumin excretion: practical advice for primary care clinicians
    George L Bakris
    University of Chicago, Pritzker School of Medicine, Chicago, IL 60637, USA
    Postgrad Med 121:51-60. 2009
    ..This article also presents an approach to managing increases in creatinine and potassium that should fit comfortably in the hands of primary care clinicians...
  51. doi request reprint Effects of angiotensin II receptor blockers on diabetic nephropathy
    Rigas Kalaitzidis
    Hypertensive Diseases Unit, University of Chicago Pritzker School of Medicine, Chicago, Illinois 60637, USA
    J Hypertens Suppl 27:S15-21. 2009
    ....
  52. doi request reprint Comparison of dual RAAS blockade and higher-dose RAAS inhibition on nephropathy progression
    George L Bakris
    University of Chicago, Pritzker School of Medicine, Hypertensive Diseases Unit, Chicago, IL, USA
    Postgrad Med 120:33-42. 2008
    ..Clinical data and ongoing trials will be discussed in the context of this hypothesis...
  53. doi request reprint The comparative effects of azilsartan medoxomil and olmesartan on ambulatory and clinic blood pressure
    George L Bakris
    Hypertensive Diseases Unit, University of Chicago Pritzker School of Medicine, Chicago, IL 60637, USA
    J Clin Hypertens (Greenwich) 13:81-8. 2011
    ..0 to -0.1; P=.038), while AZL-M 40 mg was noninferior to OLM-M 40 mg. The side effect profiles of both ARBs were similar to placebo. AZL-M is well tolerated and more efficacious at its maximal dose than the highest dose of OLM-M...
  54. ncbi request reprint Albuminuria and cardiovascular risk
    Zvezdana Bogojevic
    Rush University Medical Center, Chicago, IL 60612, USA
    Heart Fail Clin 2:53-9. 2006
  55. ncbi request reprint Rosiglitazone reduces microalbuminuria and blood pressure independently of glycemia in type 2 diabetes patients with microalbuminuria
    George L Bakris
    Rush University Medical Center, Chicago, Illinois 60612, USA
    J Hypertens 24:2047-55. 2006
    ..To test the hypothesis that rosiglitazone combined with metformin provides a greater reduction in microalbuminuria and blood pressure than metformin and glyburide at comparable levels of glycemic control...
  56. doi request reprint Role of ambulatory blood pressure monitoring in hypertension and diabetes
    Colleen Flynn
    Department of Medicine, ASH Comprehensive Hypertension Center, Section of Endocrinology, Diabetes and Metabolism, The University of Chicago Medicine, 5841 S Maryland Ave MC 1027, Chicago, IL 60637, USA
    Curr Hypertens Rep 15:137-42. 2013
    ..All new guidelines are derived from a critical evidence based evaluation of the available data...
  57. ncbi request reprint Timing and efficacy of alternative methods of sympathetic blockade
    Alexandros Briasoulis
    Department of Medicine, ASH Comprehensive Hypertension Center, The University of Chicago Medicine, Chicago, IL 60637, USA
    Curr Hypertens Rep 14:455-61. 2012
    ..e. <140/90 mmHg. The present review is focused on the clinical implications of these two technics and when they are appropriate...
  58. ncbi request reprint A comparative evaluation of various methods for microalbuminuria screening
    Pantelis A Sarafidis
    Hypertension Clinical Research Center, Department of Preventive Medicine, Rush University Medical Center, Chicago, Ill, USA
    Am J Nephrol 28:324-9. 2008
    ..We evaluated a new quantitative office-based method to assess urinary albumin excretion (UAE) and compared it to other established methods...
  59. ncbi request reprint How high should an ACE inhibitor or angiotensin receptor blocker be dosed in patients with diabetic nephropathy?
    Marc S Weinberg
    Hypertension Clinical Research Center, Rush Presbyterian St Luke s Medical Center, 1700 W Van Buren, Suite 470, Chicago, IL 60612, USA
    Curr Hypertens Rep 5:418-25. 2003
    ..The best strategy, ie, supramaximal doses of ACE inhibitors or ARBs or combining them, is still a matter of debate but may be resolved soon by results of ongoing studies...
  60. doi request reprint Dual RAAS blockade is desirable in kidney disease: con
    George L Bakris
    Department of Medicine, Hypertensive Diseases Unit, University of Chicago Pritzker School of Medicine, Chicago, Illinois, USA
    Kidney Int 78:546-9. 2010
    ..In all cases other than advanced proteinuric nephropathy, there is no evidence of any positive CKD outcome with dual RAAS blockade. Thus, dual RAAS blockade cannot be recommended for all CKD patients...
  61. ncbi request reprint Who should be treated with combination therapy as initial treatment for hypertension?
    George L Bakris
    Department of Preventive Medicine, Rush Presbyterian St Lukes Medical Center, Chicago, IL, USA
    J Clin Hypertens (Greenwich) 5:21-8. 2003
    ....
  62. doi request reprint Prehypertension: is it relevant for nephrologists?
    Rigas G Kalaitzidis
    Hypertensive Diseases Unit, Section of Endocrinology, Diabetes and Metabolism, Department of Medicine, The University of Chicago, Pritzker School of Medicine, Chicago, Illinois, USA
    Kidney Int 77:194-200. 2010
    ..Thus, nephrologists need to ensure that their colleagues appreciate the importance of not only early BP intervention but also of monitoring albuminuria changes in order to have maximal impact on CKD prevention...
  63. ncbi request reprint The importance of blood pressure control in the patient with diabetes
    George L Bakris
    Departments of Preventative and Internal Medicine, Rush Presbyterian St Luke s Medical Center, Chicago, Illinois 60612, USA
    Am J Med 116:30S-38S. 2004
    ..The new beta-blockers may play an important role in achieving blood pressure goals...
  64. doi request reprint The role of nitric oxide in improving endothelial function and cardiovascular health: focus on nebivolol
    George L Bakris
    Hypertensive Diseases Unit, Department of Medicine, University of Chicago Medical Center, Chicago, Illinois, USA
    Am J Med 123:S2-8. 2010
    ....
  65. ncbi request reprint Insulin resistance, hyperinsulinemia, and hypertension: an epidemiologic approach
    Pantelis A Sarafidis
    Hypertension Clinical Research Center, Department of Preventive Medicine, Rush University Medical Center, Chicago, IL 60612, USA
    J Cardiometab Syndr 1:334-42; quiz 343. 2006
    ..This review summarizes and evaluates the relevant epidemiologic evidence to elucidate an important aspect of the relationship between hypertension and the cardiometabolic syndrome...
  66. ncbi request reprint Is proteinuria a plausible target of therapy?
    Dave C Y Chua
    Rush University Hypertension Center, Rush University Medical Center, 1700 W Van Buren Street, Suite 470, Chicago, IL 60612, USA
    Curr Hypertens Rep 6:177-81. 2004
    ..The use of three to four different agents is frequently necessary to reach the guideline goal blood pressure of 130/80 mm Hg...
  67. ncbi request reprint Clinical implications of blockade of the renin-angiotensin system in management of hypertension
    Dave Y Chua
    Rush University Hypertension Clinical Research Center, Department of Preventive Medicine, Rush Presbyterian St Luke s Medical Center, Chicago, Ill 60612, USA
    Contrib Nephrol 143:105-16. 2004
  68. ncbi request reprint Differential effects of calcium antagonist subclasses on markers of nephropathy progression
    George L Bakris
    Rush University Hypertension Center, Chicago, Illinois 60612, USA
    Kidney Int 65:1991-2002. 2004
    ..In an earlier systematic review, calcium antagonists were shown as effective antihypertensive drugs, but there was uncertainty about their renal benefits in patients with proteinuria and renal insufficiency...
  69. ncbi request reprint Are chlorthalidone and hydrochlorothiazide equivalent blood-pressure-lowering medications?
    Nitin Khosla
    Department of Preventive Medicine, Rush Hypertension Clinical Research Center, Rush University Medical Center, Chicago, IL 60612, USA
    J Clin Hypertens (Greenwich) 7:354-6. 2005
  70. ncbi request reprint Glycemic control and cardiovascular disease in chronic kidney disease
    Suma Dronovalli
    University of Chicago Pritzker School of Medicine, Chicago, IL 60637, USA
    Curr Diab Rep 9:243-8. 2009
    ..The impact of poor glycemic control on kidney disease progression has not been well studied and should be the focus of future studies...
  71. ncbi request reprint Hypertension treatment guidelines: practical implications
    Kenneth L Choi
    Rush Hypertension Center, Department of Preventive Medicine, Rush University Medical Center, Chicago, IL 60612, USA
    Semin Nephrol 25:198-209. 2005
    ..In patients with kidney disease, reaching the BP goal requires multiple agents that should include an appropriate diuretic and an agent that blocks the renin-angiotensin-aldosterone system to slow the progression of kidney disease...
  72. ncbi request reprint Achieving goal blood pressure in patients with type 2 diabetes: conventional versus fixed-dose combination approaches
    George L Bakris
    Department of Preventive Medicine, Rush Presbyterian St Lukes Medical Center, Chicago, IL 60612, USA
    J Clin Hypertens (Greenwich) 5:202-9. 2003
    ..A fixed-dose combination approach appears as safe as the current conventional approaches...
  73. ncbi request reprint Microalbuminuria: marker of vascular dysfunction, risk factor for cardiovascular disease
    Jay P Garg
    Rush Presbyterian St Luke s Medical Center, Department of Preventive Medicine, Hypertensison Clinical Research Center, Chicago, IL 60612, USA
    Vasc Med 7:35-43. 2002
    ..Achieving such a goal with agents that also impact microalbuminuria will provide for a more complete cardiovascular risk reduction...
  74. ncbi request reprint Pathogenesis and clinical physiology of hypertension
    George L Bakris
    Rush University Hypertension Clinical Research Center, Department of Preventive Medicine, Rush Presbyterian St Luke s Medical Center, 1700 West Van Buren Street, Suite 470, Chicago, IL 60612, USA
    Cardiol Clin 20:195-206, v. 2002
    ....
  75. ncbi request reprint Angiotensin converting enzyme inhibitors or angiotensin receptor blockers in nephropathy from type 2 diabetes
    Jay Garg
    Rush Medical Center, 1700 W Van Buren Street, Suite 470, Chicago, IL 60612, USA
    Curr Hypertens Rep 4:185-90. 2002
    ..5 mg/dL, should be placed on an ACE inhibitor for cardiovascular risk reduction. If nephropathy is present, the evidence would support an ARB for therapy in concert with a b-blocker for cardiovascular risk reduction and renoprotection...
  76. ncbi request reprint Achieving blood pressure goals: is fixed-dose combination therapy the answer?
    George L Bakris
    Department of Preventive Medicine, Rush Presbyterian St Lukes Medical Center, Chicago, IL, USA
    J Clin Hypertens (Greenwich) 5:2-3. 2003
  77. ncbi request reprint ACE inhibitors and protection against kidney disease progression in patients with type 2 diabetes: what's the evidence
    George L Bakris
    Department of Preventive Medicine, Rush Presbyterian St Lukes Medical Center, Chicago, IL 60612, USA
    J Clin Hypertens (Greenwich) 4:420-3. 2002
    ..This review critically evaluates the limited evidence in support of angiotensin-converting enzyme inhibitors as renal-protective agents in people with type 2 diabetes...
  78. ncbi request reprint Hypertension and nephropathy
    George L Bakris
    Hypertension Clinical Research Center, Rush Presbyterian St Luke s Medical Center, Chicago, Illinois 60612, USA
    Am J Med 115:49S-54S. 2003
    ..In patients with type 2 diabetes, early use of TZDs may be beneficial in both achieving glucose control and reducing the development or worsening of microalbuminuria or hypertension...
  79. ncbi request reprint Should beta-blockers be used to control hypertension in people with chronic kidney disease?
    Peter D Hart
    Division of Nephrology, Department of Medicine, Cook County Hospital, Chicago, IL, USA
    Semin Nephrol 27:555-64. 2007
    ..In addition, carvedilol may retard progression of albuminuria, and provide cardiorenal protection in chronic kidney disease patients with hypertension, congestive heart failure, and at high risk for sudden cardiac death...
  80. ncbi request reprint Effects of COX inhibition on blood pressure and kidney function in ACE inhibitor-treated blacks and hispanics
    Munavvar Izhar
    Rush Medical Center, 1700 W Van Buren St, Suite 470, Chicago, IL 60612, USA
    Hypertension 43:573-7. 2004
    ..Differences observed in blood pressure response between COX inhibitors may not be related in their sensitivity but rather their dosing frequency...
  81. ncbi request reprint Calcium antagonists: effects on cardio-renal risk in hypertensive patients
    Sandeep Nathan
    Department of Preventive Medicine, Hypertension Clinical Research Center, Rush University Medical Center, Chicago, IL 60612, USA
    Hypertension 46:637-42. 2005
    ....
  82. ncbi request reprint Barriers to blood pressure control in African Americans. Overcoming obstacles is challenging, but target goals can be attained
    Janice G Douglas
    Division of Hypertension, Department of Medicine, Case Western Reserve University School of Medicine, University Hospitals of Cleveland, Room W165, 10900 Euclid Ave, Cleveland, OH 44106 4982, USA
    Postgrad Med 112:51-2, 55, 59-62 passim. 2002
    ..When extensive efforts to achieve blood pressure control prove unattainable in the primary care setting, consultation with a hypertension specialist should be considered...
  83. ncbi request reprint Slowing the progression of diabetic nephropathy and its cardiovascular consequences
    Peter A McCullough
    Division of Nutritional and Preventive Medicine, William Beaumont Hospital, Beaumont Health Center, 4949 Coolidge, Royal Oak, MI 48073, USA
    Am Heart J 148:243-51. 2004
    ..The goal of an ideal clinical trial would be ESRD prevention; however, pragmatic objectives such as a greater understanding of therapeutic toxicities should also be explored in this population...
  84. ncbi request reprint Hypertension and diabetes: family physicians' pivotal role
    George L Bakris
    Am Fam Physician 66:1151-2. 2002
  85. ncbi request reprint Management of high blood pressure in African Americans: consensus statement of the Hypertension in African Americans Working Group of the International Society on Hypertension in Blacks
    Janice G Douglas
    Case Western Reserve University, Department of Medicine, Room W 165, 10900 Euclid Ave, Cleveland, Ohio 44106, USA
    Arch Intern Med 163:525-41. 2003
  86. ncbi request reprint Hypertension-related disease in African Americans. Factors underlying disparities in illness and its outcome
    James R Sowers
    Departments of Medicine, Biochemistry, and Cell Biology, State University of New York Health Science Center, Brooklyn College of Medicine, Brooklyn, NY 11203, USA
    Postgrad Med 112:24-6, 29-30, 33-4 passim. 2002
    ..In this article, Drs Sowers, Ferdinand, Bakris, and Douglas examine the biologic, social, and genetic factors that contribute to these health disparities, the risk for which appears in early childhood...
  87. ncbi request reprint Type 2 diabetes: RENAAL and IDNT--the emergence of new treatment options
    Domenic A Sica
    Section of Clinical Pharmacology and Hypertension, Division of Nephrology, Medical College of Virginia of Virginia Commonwealth University, Richmond, VA 23298 1060, USA
    J Clin Hypertens (Greenwich) 4:52-7. 2002
    ..An evidence-based therapeutic approach derived from these trials would argue for ARBs to be the foundation of therapy in the patient with type 2 diabetes and nephropathy...
  88. ncbi request reprint The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report
    Aram V Chobanian
    Department of Medicine, Boston University School of Medicine, Boston, Mass, USA
    JAMA 289:2560-72. 2003
    ..Empathy builds trust and is a potent motivator. Finally, in presenting these guidelines, the committee recognizes that the responsible physician's judgment remains paramount...
  89. ncbi request reprint Proteinuria and other markers of chronic kidney disease: a position statement of the national kidney foundation (NKF) and the national institute of diabetes and digestive and kidney diseases (NIDDK)
    Garabed Eknoyan
    Department of Medicine, Baylor College of Medicine, Houston, TX, USA
    Am J Kidney Dis 42:617-22. 2003
  90. ncbi request reprint Quality of life measured in a practice-based hypertension trial of an angiotensin receptor blocker
    Michael A Weber
    State University of New York Downstate College of Medicine, Brooklyn, NY 11203, USA
    J Clin Hypertens (Greenwich) 5:322-9. 2003
    ..001 for each) with the increases in the GWBI scores. Controlling blood pressure appears to be an important element in improving subjective health perceptions of hypertensive patients...
  91. ncbi request reprint Amlodipine and valsartan combined and as monotherapy in stage 2, elderly, and black hypertensive patients: subgroup analyses of 2 randomized, placebo-controlled studies
    Timothy R Smith
    Mercy Health Research, Washington University School of Medicine, St Louis, MO 63141, USA
    J Clin Hypertens (Greenwich) 9:355-64. 2007
    ..These findings were consistent with the primary efficacy analysis results from the overall study populations. Combination regimens were generally well tolerated by all patient subgroups...
  92. ncbi request reprint Baseline characteristics in the Avoiding Cardiovascular events through Combination therapy in Patients Living with Systolic Hypertension (ACCOMPLISH) trial: a hypertensive population at high cardiovascular risk
    Michael A Weber
    SUNY Downstate Medical College, 420 Lexington Avenue, Brooklyn, NY 10170, USA
    Blood Press 16:13-9. 2007
    ..It is noteworthy that the mean BMI of 31 in this cohort is clearly above the accepted diagnostic criterion of obesity and that 60% of patients are diabetic, possibly reflecting secular trends in clinical disease...
  93. ncbi request reprint Intervention at lower blood pressure levels to achieve target goals in type 2 diabetes: PRADID (PResi├│n Arterial en DIab├ęticos tipo Dos) study
    Luis M Ruilope
    Hypertension Unit, Hospital 12 du Octubre, Madrid, Spain
    J Hypertens 22:217-22. 2004
    ....
  94. ncbi request reprint Predictors of development of diabetes mellitus in patients with coronary artery disease taking antihypertensive medications (findings from the INternational VErapamil SR-Trandolapril STudy [INVEST])
    Rhonda Cooper-DeHoff
    University of Florida College of Medicine, Gainesville, Florida, USA
    Am J Cardiol 98:890-4. 2006
    ....
  95. ncbi request reprint Efficacy and safety of coadministered amlodipine and atorvastatin in patients with hypertension and dyslipidemia: results of the AVALON trial
    Franz H Messerli
    St Luke s Roosevelt Hospital Center, New York, NY 10019, USA
    J Clin Hypertens (Greenwich) 8:571-81; quiz 582-3. 2006
    ..Concomitant administration of amlodipine and atorvastatin is an effective and well tolerated treatment for coexisting hypertension and dyslipidemia...
  96. ncbi request reprint Antihypertensive efficacy of Irbesartan/HCTZ in men and women with the metabolic syndrome and type 2 diabetes
    James R Sowers
    University of Missouri Columbia and Harry S Truman VA Medical Center, 65212, USA
    J Clin Hypertens (Greenwich) 8:470-80. 2006
    ..Irbesartan/HCTZ fixed combinations achieved SBP goals in over half of the T2DM patients and nearly three quarters of patients with the metabolic syndrome, with SBP uncontrolled on antihypertensive monotherapy...
  97. ncbi request reprint Do the metabolic effects of beta blockers make them leading or supporting antihypertensive agents in the treatment of hypertension?
    Panteleimon A Sarafidis
    1st Department of Preventive Medicine, AHEPA Hospital, Aristotle University of Thessaloniki, Greece
    J Clin Hypertens (Greenwich) 8:351-6; quiz 357-8. 2006
    ....
  98. ncbi request reprint The effect of ruboxistaurin on nephropathy in type 2 diabetes
    Katherine R Tuttle
    Research Department, The Heart Institute and Sacred Heart Medical Center, Spokane, WA 99204 2340, USA
    Diabetes Care 28:2686-90. 2005
    ..Ruboxistaurin selectively inhibits protein kinase C-beta and ameliorates kidney disease in animal models of diabetes. The purpose of this study was to evaluate the effects of ruboxistaurin on diabetic nephropathy in humans...
  99. ncbi request reprint Effect of fixed-dose ACE-inhibitor/calcium channel blocker combination therapy vs. ACE-inhibitor monotherapy on arterial compliance in hypertensive patients with type 2 diabetes
    Nathaniel Winer
    SUNY Downstate Medical Center, Brooklyn, NY 11203, USA
    Prev Cardiol 8:87-92. 2005
    ..05). No significant change in small-vessel compliance was observed with either treatment. Greater improvement in large-vessel compliance with combination therapy was independent of BP lowering...
  100. ncbi request reprint The relationship between magnitude of proteinuria reduction and risk of end-stage renal disease: results of the African American study of kidney disease and hypertension
    Janice Lea
    Department of Medicine, Emory University School of Medicine, Atlanta, GA, USA
    Arch Intern Med 165:947-53. 2005
    ..The objective of this study was to relate baseline and early changes in proteinuria and glomerular filtration rate (GFR) to long-term progression of hypertensive nondiabetic kidney disease...
  101. ncbi request reprint Amlodipine/benazepril combination therapy for hypertensive patients nonresponsive to benazepril monotherapy
    Steven G Chrysant
    Oklahoma Cardiovascular and Hypertension Center and the University of Oklahoma School of Medicine, Oklahoma City, Oklahoma 73132, USA
    Am J Hypertens 17:590-6. 2004
    ....